Severe veno-occlusive disease (VOD), or sinusoidal obstruction syndrome (SOS), is a significant cause of post-HSCT morbidity and mortality. This complication typically develops predominantly in the first 21 days of HSCT, although pediatric onset may be later in 15-20% [1] . Severe VOD/SOS leads to multi-organ failure (MOF), in which mortality exceeds 80% [2, 3] .
The incidence of SOS/VOD in children after HSCT varies widely in reports, ranging from 8 to 60% [1, 4, 5] . The diagnosis is typically made by clinical observations as outlined by the Baltimore or the modified Seattle criteria [6, 7] . The Baltimore criteria are based on the presence of hyperbilirubinemia (>2 mg/dL) and 2 of the following: weight gain >5% from baseline, hepatomegaly, or ascites. The modified Seattle criteria require any 2 of the following: hyperbilirubinemia (2 mg/dL), ascites and/or unexplained weight gain of >2% from baseline or hepatomegaly and right upper quadrant pain. Reversal of portal flow by ultrasound is commonly noted, although this is not pathognomonic nor included in the Baltimore or modified Seattle criteria.
The treatment of SOS/VOD in children is highly variable, as noted in a recent survey [8] . Until recently, management included supportive care only, as thrombotic agents were not effective and also increased the risk of bleeding. Defibrotide, an anti-thrombotic with antiinflammatory and anti-ischemic properties, is the only definitive therapy available for severe VOD/SOS. In international multicenter phase II and III clinical trials, treatment of severe VOD/SOS with defibrotide resulted in complete remission in 36-56% [9, 10] . However, outcomes in this patient population still remain suboptimal, with mortality occurring primarily from respiratory and/or renal failure and MOF.
Ascites develops in 20-80% of children with SOS/VOD and may be contribute to multi-organ failure (MOF) with respiratory compromise from abdominal competition and renal dysfunction from vascular compression [8] . Diuretics may be of limited benefit due to intra-vascular dehydration. Drainage of ascites can improve respiratory excursion and prevent renal injury from intra-abdominal hypertension and impaired renal perfusion, but is not standard of care [8] . A recent retrospective study by Madenci et al [4] . reviewed the safety of pleural and peritoneal drain placement in pediatric HSCT patients with severe SOS/VOD. However, there was limited information about its utility when used with defibrotide in preventing MOF. We describe clinical features and outcomes in pediatric patients who developed SOS/VOD and received PD, in comparison to those who did not receive PD. All patients were treated with defibrotide.
Subjects and methods
We carried out an institutional review board (IRB) approved retrospective chart review of all patients (ages 0-21 years) who developed severe SOS/VOD following HSCT, and received defibrotide at a single pediatric institution. These patients underwent HSCT from January 2006 through April 2016, and included patients who developed severe SOS/VOD based upon the Baltimore or Seattle diagnostic criteria. These patients were enrolled on IRB and FDA approved defibrotide studies, including four on the pivotal trial (NCT00358501) and 40 on the compassionate use trial (NCT00628498). The primary outcome included overall survival at day 100 and death from complications from SOS/VOD. The secondary outcome included development of complications such as infection or bleeding from PD.
Routine supportive care for patients with SOS/VOD on defibrotide at the Children's Hospital of Philadelphia included sodium restriction, diuretics after blood products, and maintenance of platelets >30 × 10 5 /μL. The decision to place a peritoneal drain was based upon increasing ascites and patient clinical condition.
For allogeneic recipients, conditioning included total body irradiation (1200 cGy/6 fractions) or intravenous busulfan for 16 doses with pharmacokinetics to maintain a steady state between 600-900 ng/mL (Table 1) with cyclophosphamide or fludarabine for non-malignant disease. Graft-vs-host disease prophylaxis included in vitro T lymphocyte depletion and cyclosporine for recipients of unrelated donor peripheral stem cells, cyclosporine/ methotrexate for bone marrow recipients and cyclosporine/methylprednisolone for cord blood recipients. Autologous recipients, all of whom had neuroblastoma, received either carboplatin/etoposide/ melphalan (56.3%) or busulfan/melphalan with busulfan pharmacokinetics.
Categorical variables were summarized by frequency and percent, and were compared by groups using Χ 2 tests (e.g., compare death by PD vs. no PD). Continuous variables were summarized by median and range, and were compared by groups using Wilcoxon test (e.g., compare weight gain by PD vs. no PD). A two-sided p value < 0.05 was considered statistically significant. All the analyses were performed in SAS 9.3.
A total of 44 patients met the definition of SOS/VOD and received defibrotide. This comprised 5.7% of all allogeneic and neuroblastoma transplants during that time period. Clinical features and diagnoses of these patients are shown in Table 1 . Median age of patients who received allogeneic transplants was higher than those who received autologous transplants (p = 0.03).
Ultrasound evaluations showed ascites in all patients, and reversal of portal flow for 27 (61.3%) patients (Table 2 ). Of note, more patients with reversal of flow (ROF) underwent PD than those without ROF. Treatment with defibrotide for the entire cohort began at a median of 16 days (range, 7-72) after transplant and the treatment was continued for a median of 20 (3-51) days.
Of the total cohort, six patients with neuroblastoma and 12 allogeneic recipients had peritoneal drains placed. Indications for PD placement included increasing respiratory distress and/or decreased urine output from ascites/abdominal competition and increasing pain from ascites. Peritoneal drains were placed post SOS/VOD diagnosis at a median of 4.5 days (range, 0-22), and the drain was removed after 3-61 days (median, 13). The initial amount of peritoneal fluid drained was weight dependent, and drains were left to gravity. Up to 2 L was drained initially in patients over 30 kg. There were no cardiovascular complications from peritoneal drainage, and no patient required albumin or other fluid for replacement due to hypotension. There was no excessive bleeding or infection from the PDs.
Twenty-three patients (52.3%) required transfer to the intensive care unit (ICU) and seventeen of these patients (73.9%) required vasopressors during their ICU stay. Table 2 lists other supportive care measures that were necessary for these patients. Ten patients died before day 100 (22.7%), including three following second or third HSCT. Four of these patients had received PD. Causes of death included MOF from VOD (6), intracranial hemorrhage/VOD in a patient with congenital thrombocytopenia (1), and infection (3) .
Statistical analysis showed no significant differences in weight gain or bilirubin levels at SOS/VOD diagnosis in those who received PD compared to those who did not (Table 2 ). There was no significant difference in outcomes between patients who underwent PD placement and those who did not. However, there were more patients in the PD group who had portal reversal of flow on ultrasound than those who did not undergo PD (= −0.026).
Ascites develops in 20-80% of children with SOS/VOD and can result in severe morbidity [3, 4] . Progressive ascites increases risks of respiratory compromise due to abdominal competition, and renal compromise due to compression of renal vasculature. Management of ascites generally has consisted of primarily supportive care measures, including fluid restriction, diuretics to minimize ascites and renal (2), sickle cell disease (1) hemophagocytic lymphohistiocytosis (1), adrenoleukodystrophy (1) replacement therapy. Defibrotide is the most effective agent for treating SOS/VOD. The most recent prospective study of defibrotide for treatment of severe SOS showed that its use was associated with a complete resolution in 25.5% of patients compared to 12.5% of the control group (p = 0.016) with a statistically superior day-100 survival [8, 10] . Even with defibrotide, supportive care remains a cornerstone of effective SOS/VOD therapy, as resolution of ascites may take many days, with resultant renal and respiratory compromise [11] . There is little data on the use and safety of interventional strategies, including PD, for prevention of MOF. A study by Madenci et al [4] . evaluated the safety of peritoneal and pleural drain placement in pediatric HSCT recipients with severe SOS. They found no procedural complications related to either procedure, and there was no associated increase in overall mortality. In our study, 40.9% of patients with severe SOS/VOD and treated with defibrotide had peritoneal drains placed. Our study is too small to determine an effect of PD placement on outcome, but the larger number of patients who had reversal of flow in the PD group suggests increased disease severity. The day +100 survival was 81% in the PD group, and this day +100 survival compares favorably to that reported in the literature, and may be due to early initiation of defibrotide and PD. Using ROF as a marker of severity, there were more patients with severe VOD/SOS in the PD group, with encouraging outcomes. No deaths were related to procedural complications.
In conclusion, SOS/VOD remains a significant complication of HSCT with mortality in severe cases of about 50%. Supportive care with the use of peritoneal drains in patients with progressive or symptomatic ascites plays a role in decreasing morbidity and mortality by optimizing pulmonary and renal function. Additional studies are needed in a larger setting especially to define the appropriate timing of paracentesis and PD, and defining criteria to identify patients at high risk of complications from SOS/ VOD-related ascites to determine who will benefit most from this procedure. 
